Physician profile
Ronny Yip
NPI 1891445003
$2,033.23
in general payments reported to CMS, 2019-2025
21 companies · $759 in 2025
The $759 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $289 · 2024: $861 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $401.60 | 2023-2025 | Fintepla, Zilbrysq, Rystiggo |
| Sk Life Science, INC. | $232.83 | 2023-2025 | |
| Abbvie INC. | $216.32 | 2023-2025 | |
| Neurelis, INC. | $202.24 | 2023-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $180.08 | 2024-2025 | |
| Amgen INC. | $153.03 | 2024-2025 | Uplizna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2022 | |
| Ceribell, INC. | $110.78 | 2024 | Pocket Eeg Device |
| Merz Pharmaceuticals, LLC | $84.99 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Neurocrine Biosciences, INC. | $49.32 | 2025 | |
| Acorda Therapeutics, INC | $38.06 | 2023 | Inbrija |
| Vanda Pharmaceuticals INC. | $31.90 | 2025 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $30.80 | 2023 | Austedo Xr |
| Tanabe Pharma America, INC. | $26.33 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $25.33 | 2024 | Wainua |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $24.50 | 2025 | Ultomiris |
| Janssen Biotech, INC. | $23.77 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.04 | 2023 | |
| Tg Therapeutics, INC. | $20.26 | 2024 | |
| Lundbeck LLC | $17.14 | 2024 | Vyepti |
| Mallinckrodt Hospital Products INC. | $15.91 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronny Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.